Warren Buffett says these are the very best businesses to own — 3 high-quality examples from Berkshire’s portfolio

TipRanks

Novavax: All Eyes on Upcoming FDA Advisory Meeting

It’s difficult for most stocks to make any headway in 2022. Inflation, rising interest rates and Russia’s ongoing war on Ukraine have dragged down even those with minimal exposure to the macro headwinds. For Novavax (NVAX), these worries have been amplified by other considerations. First, there is the prospect of dwindling global demand for Covid-19 vaccines, what with the virus on the backfoot in many parts of the world and there being an oversupply in selected regions. Secondly, in the U.S. at